<div><div><h2>Buy Sun Pharma; target of Rs 760: Motilal Oswal</h2></div><div>"motilal oswal's research report on sun pharmadomestic formulation sales disappoint: 2qfy19 revenue grew moderately by ~4% yoy to inr68.5b (our estimate: inr75.5b). the miss in revenue is primarily attributable to de-growth in domestic business (~28% of sales) on the back of one-time inventory reduction in supply chain. us business (~36% of sales) grew by a healthy ~11% yoy in constant currency. gross margin improved by ~280bp yoy (+380bp qoq) to 74.3% largely due to lower cogs for taro and write-back of certain provisions taken earlier. ebitda margin expanded by ~110bp yoy (-30bp qoq) to 21%. sunp reported a loss of inr2.2b during the quarter due to one-time provision of inr12.1b related to the modafinil anti-trust litigation. adjusted for this pat was up ~9% yoy to inr9.9b (our estimate: inr10.9b). for 1hfy19 sales/ebitda/pat increased 10%/27%/38% yoy to inr141.6b/inr31.4b/inr19.8b.outlookwe remain positive on sunp considering likely ramp-up of specialty products increased approvals from halol and good potential in domestic formulation. maintain buy.for all recommendations report click heredisclaimer: the views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own and not that of the website or its management. moneycontrol.com advises users to check with certified experts before taking any investment decisions.sun pharma_201118"</div></div>